SciBase Holding AB (SciBase) (STO:SCIB), a developer of augmented intelligence-based solutions for skin disorders, revealed on Wednesday that it has entered into a collaboration agreement with Schweiger Dermatology group (SDG) to pilot the Nevisense skin cancer detection test at SDG's Freehold, NJ office.

Nevisense is reportedly the only FDA approved test for early melanoma detection at point-of-care.

According to SciBase, SDG is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.

Simon Grant, CEO of SciBase, stated: "We are very pleased to announce our collaboration with Schweiger Dermatology Group. In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group's Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology. For SciBase, we establish a further partner that helps introduce Nevisense to US payers."